about
New generation antipsychotics for first episode schizophreniaQuantitative levels of aripiprazole parent drug and metabolites in urine.Novel antipsychotics in the long-term treatment of schizophrenia.Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyAripiprazole: a review of its use in the management of schizophrenia in adults.Improving treatment adherence in your patients with schizophrenia: the STAY initiative.Novel remote electronic medication supply model for opioid-dependent outpatients with polypharmacy--first long-term case study.Relationship of clinical symptoms and substance use in schizophrenia patients on conventional versus atypical antipsychotics.A prospective study of noncompliance with medication, suicidal ideation, and suicidal behavior in recently discharged psychiatric inpatients.Colonic architectural change on colonoscopy in patients taking psychotropic medications.Long-term treatment with flupentixol results of a post-marketing surveillance study.Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride.Community Treatment Orders (CTOs): a demographic cross-sectional analysis.Communication between people with schizophrenia and their medical professionals: a participatory research project.[Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].
P2860
Q24247720-391204B9-039B-4259-A565-0306B49BE015Q34459567-FF030B2F-FAAA-45BC-8D31-0578F84FFE05Q35719339-F185B303-B41C-4CC8-8F8B-786EC7697004Q35736374-EDDBBBB6-812C-446F-994D-4A5BD0EED9E3Q35841195-149DABCD-AF63-47F4-BAF7-7FD89F92F6DCQ37980517-BB445C1C-51FC-4772-BE97-ED073B1D45F4Q38071595-6F3A7E5F-52A7-4A55-8128-F768FCBDF417Q40081065-F9973D0F-B047-406F-BB43-F6B542871355Q44596380-64979131-AAFA-455A-903F-88A7CB61269BQ44739518-461EEAF9-E7F9-4483-901F-718E6C51E25FQ46132157-E52F6076-39DF-4461-8990-60AE8C1C98A8Q46533489-7FEA2730-E907-4900-B87A-C2BFB2EC7D36Q46886092-5FD6AF70-A5EF-46A8-B553-D609E72C2691Q50563776-C2F4F8E9-B6A5-4FFB-B354-13C9C356DBD4Q51941847-CA995580-7BEB-444A-AEE3-9753E9E0F4B8Q53654663-CD0294B8-B131-465B-9AA3-0C5B0B1154FF
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Compliance with antipsychotic treatment
@ast
Compliance with antipsychotic treatment
@en
type
label
Compliance with antipsychotic treatment
@ast
Compliance with antipsychotic treatment
@en
prefLabel
Compliance with antipsychotic treatment
@ast
Compliance with antipsychotic treatment
@en
P2093
P2860
P1476
Compliance with antipsychotic treatment
@en
P2093
W. W. Fleischhacker
P2860
P356
10.1034/J.1600-0447.2000.00016.X
P407
P577
2000-12-01T00:00:00Z